03.19.2019 Issue 443

   
Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

ICER Releases Updated Protocol
for Assessing Price Hikes

Friday, March 15

ICER released an updated protocol for its planned annual analysis of drug price hikes to determine which are and aren't supported by clinical evidence.

Article on Drug Prices Spurs Debate

Gottlieb Slams Sponsors Over Unwillingness to Rethink Trials

Legislators Target Anti-Competitive Practices

Article: FDA, Gottlieb Pushed on RWE


Senior Research Analyst (HEOR)

Scientific Writer

Medical Statistician

Health Economics & Real-World Evidence (HE-RWE) Scientist

Industry Spotlight


Conferences Webinars
Patient Partnering in Clinical Development
    March 19-20, Berlin, Germany

Pharma Pricing and Market Access Congress 2019
    March 19-20, Amsterdam, Netherlands

Indication-Based Pricing Masterclass: Delivering the Win-Win
    March 20, London, U.K.

Life Sciences Accounting and Reporting Congress
    March 20-22, Philadelphia, Pennsylvania

On the Rise: Out-of-Pocket Healthcare Spending
    March 20

Metadata-Driven Approach for Clinical Data Lakes
    March 21

Conquering the Missing Factor in Hemophilia A: New Evidence and Management Strategies for Patients With and Without Inhibitors
    March 21

ISPOR Educational Webinar: Top 10 Trends in HEOR
    March 22


Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Review of Influence: The Institute for Clinical and Economic Review

Innovative Drugs: Mapping the Pricing and Reimbursement Landscape

Orphan Drugs: European Payer Perspectives

Do Payers Really Want Pay-for-Performance?

Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs, Biologics

Blockchain: Transformational Change for Pharma?

2018 Specialty Drug Trends

The Global Use of Medicine in 2019 and Outlook to 2023

Breaking Through the Hype of Real-World Evidence

Time to Market: Accelerating Market Access

Orphan Drugs in the United States

Charting Real World Data and Evidence – Activity and Capabilities (2018)


 
Special Thanks to Our Partners:
             Truven    
              Evidera    HealthCore    University of FL
Xcenda    OM1    Parexel    Jefferson     Dymaxium
Precision Xtract    Pharmerit    eMax Health    Sciformix
Evidence Partners     ICON
Share this newsletter on social media:

Email Twitter Facebook LinkedIn